The striking part isn’t just that a 14‑protein panel can flag lung cancer risk >5 years out, it’s that the signal is so IL‑1β‑centric. That neatly retrofits the CANTOS “accident” where canakinumab cut lung cancer incidence and mortality. We’re basically watching systemic inflammation turn the lung microenvironment pro‑tumor long before a nodule appears on CT. The next step isn’t more imaging, it’s immunoprevention trials in the high‑signature group.